Ardelyx Inc. | Small-cap | Healthcare
$5.60
3.70%
| Ardelyx Stock Comparison:
Ardelyx vs VertexArdelyx vs RegeneronArdelyx vs Harmony BiosciencesArdelyx vs Cg OncologyArdelyx vs CelcuityArdelyx vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 97.7M
Gross Profit 85.3M 87.30%
Operating Income -14.4M -14.74%
Net Income -19.1M -19.54%
EPS (Diluted) $-0.08

Balance Sheet Metrics

Total Assets 410.2M
Total Liabilities 264.5M
Shareholders Equity 145.7M
Debt to Equity 1.82

Cash Flow Metrics

Operating Cash Flow -33.0M
Free Cash Flow -38.8M

Revenue & Profitability Trend

Ardelyx Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i333.6M124.5M52.2M10.1M7.6M
Cost of Goods Sold i50.6M17.8M4.1M1.0M145.0K
Gross Profit i283.1M106.7M48.0M9.1M7.4M
Gross Margin % i84.8%85.7%92.1%90.1%98.1%
Operating Expenses
Research & Development i52.3M35.5M35.2M91.1M65.1M
Selling, General & Administrative i258.7M134.4M76.6M72.3M33.2M
Other Operating Expenses i-----
Total Operating Expenses i311.0M169.9M111.8M163.4M98.2M
Operating Income i-28.0M-63.3M-63.8M-154.3M-90.8M
Operating Margin % i-8.4%-50.8%-122.2%-1,528.6%-1,199.0%
Non-Operating Items
Interest Income i-----
Interest Expense i20.1M8.9M5.1M4.5M5.1M
Other Non-Operating Income9.2M6.6M1.6M687.0K1.6M
Pre-tax Income i-38.9M-65.5M-67.2M-158.2M-94.3M
Income Tax i266.0K547.0K8.0K4.0K2.0K
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-39.1M-66.1M-67.2M-158.2M-94.3M
Net Margin % i-11.7%-53.1%-128.9%-1,566.5%-1,245.7%
Key Metrics
EBITDA i-16.7M-55.4M-61.0M-150.9M-86.7M
EPS (Basic) i$-0.17$-0.30$-0.42$-1.52$-1.05
EPS (Diluted) i$-0.17$-0.30$-0.42$-1.52$-1.05
Basic Shares Outstanding i23523292721933125315869008310420564589582138
Diluted Shares Outstanding i23523292721933125315869008310420564589582138

Income Statement Trend

Ardelyx Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i64.9M21.5M96.1M72.4M91.0M
Short-term Investments i185.2M162.8M27.8M44.3M95.5M
Accounts Receivable i57.7M22.0M7.7M502.0K0
Inventory i21.2M12.4M3.3M0-
Other Current Assets11.1M8.4M5.1M7.1M8.2M
Total Current Assets i356.5M246.1M153.6M133.6M194.7M
Non-Current Assets
Property, Plant & Equipment i2.4M5.6M9.3M20.2M9.5M
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets75.4M40.6M25.9M1.2M552.0K
Total Non-Current Assets i79.3M51.5M36.5M16.3M6.9M
Total Assets i435.8M297.6M190.1M149.9M201.6M
Liabilities
Current Liabilities
Accounts Payable i16.0M11.1M10.9M4.3M5.6M
Short-term Debt i1.6M4.4M30.6M35.8M6.3M
Current Portion of Long-term Debt-----
Other Current Liabilities8.8M2.0M2.5M1.2M1.7M
Total Current Liabilities i77.8M50.4M65.6M52.8M28.4M
Non-Current Liabilities
Long-term Debt i151.9M51.5M5.9M9.7M47.0M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities-----
Total Non-Current Liabilities i184.6M80.4M26.1M14.5M47.0M
Total Liabilities i262.5M130.8M91.7M67.3M75.4M
Equity
Common Stock i24.0K23.0K20.0K13.0K9.0K
Retained Earnings i-885.3M-846.2M-780.1M-712.9M-554.8M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i173.3M166.8M98.3M82.6M126.1M
Key Metrics
Total Debt i153.4M56.0M36.5M45.5M53.3M
Working Capital i278.6M195.7M88.0M80.8M166.3M

Balance Sheet Composition

Ardelyx Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-39.1M-66.1M-67.2M-158.2M-94.3M
Depreciation & Amortization i2.1M1.3M1.1M2.8M2.5M
Stock-Based Compensation i37.4M13.5M10.8M12.0M10.6M
Working Capital Changes i-75.0M-36.5M-24.0M-4.2M1.2M
Operating Cash Flow i-70.6M-82.8M-73.2M-144.8M-77.4M
Investing Activities
Capital Expenditures i-1.0M-344.0K1.7M-1.9M-324.0K
Acquisitions i-----
Investment Purchases i-195.2M-215.2M-50.3M-72.7M-150.9M
Investment Sales i177.9M84.3M67.0M125.6M119.7M
Investing Cash Flow i-18.3M-131.2M18.4M50.9M-31.4M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i99.5M22.4M27.0M00
Debt Repayment i00-33.0M-19.4M-125.0K
Financing Cash Flow i98.5M145.1M75.1M81.6M20.9M
Free Cash Flow i-45.8M-90.1M-70.1M-154.4M-81.8M
Net Change in Cash i9.5M-69.0M20.4M-12.2M-87.9M

Cash Flow Trend

Ardelyx Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -33.82
Forward P/E -82.43
Price to Book 9.95
Price to Sales 3.60
PEG Ratio -82.43

Profitability Ratios

Profit Margin -14.60%
Operating Margin -14.74%
Return on Equity -39.36%
Return on Assets -6.23%

Financial Health

Current Ratio 4.30
Debt to Equity 167.99
Beta 0.68

Per Share Data

EPS (TTM) $-0.24
Book Value per Share $0.58
Revenue per Share $1.62

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
ardx1.4B-33.829.95-39.36%-14.60%167.99
Vertex 94.0B26.035.4722.77%31.86%8.89
Regeneron 59.7B14.181.9615.34%31.37%9.04
Harmony Biosciences 2.0B11.032.5427.58%23.42%22.43
Cg Oncology 1.9B-18.792.90-12.00%0.00%0.15
Celcuity 2.2B-18.5123.01-115.39%0.00%113.89

Financial data is updated regularly. All figures are in the company's reporting currency.